Updated Phase 1 data include a 16.3-month median recurrence-free survival (“mRFS”) and 28.9-month median overall survival (“mOS”) from full study ...
Elicio is tackling this challenge with next-generation immunotherapies based on its proprietary Amphiphile (AMP) technology, which can effectively ferry immunomodulatory payloads—from small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback